Theranostic nanomedicine.

Nanomedicine formulations aim to improve the biodistribution and the target site accumulation of systemically administered (chemo)therapeutic agents. Many different types of nanomedicines have been evaluated over the years, including for instance liposomes, polymers, micelles and antibodies, and a significant amount of evidence has been obtained showing that these submicrometer-sized carrier materials are able to improve the balance between the efficacy and the toxicity of therapeutic interventions. Besides for therapeutic purposes, nanomedicine formulations have in recent years also been increasingly employed for imaging applications. Moreover, paralleled by advances in chemistry, biology, pharmacy, nanotechnology, medicine and imaging, several different systems have been developed in the last decade in which disease diagnosis and therapy are combined. These so-called (nano) theranostics contain both a drug and an imaging agent within a single formulation, and they can be used for various different purposes. In this Account, we summarize several exemplary efforts in this regard, and we show that theranostic nanomedicines are highly suitable systems for monitoring drug delivery, drug release and drug efficacy. The (pre)clinically most relevant applications of theranostic nanomedicines relate to their use for validating and optimizing the properties of drug delivery systems, and to their ability to be used for pre-screening patients and enabling personalized medicine. Regarding the former, the combination of diagnostic and therapeutic agents within a single formulation provides real-time feedback on the pharmacokinetics, the target site localization and the (off-target) healthy organ accumulation of nanomedicines. Various examples of this will be highlighted in this Account, illustrating that by non-invasively visualizing how well carrier materials are able to deliver pharmacologically active agents to the pathological site, and how well they are able to prevent them from accumulating in potentially endangered healthy tissues, important information can be obtained for optimizing the basic properties of drug delivery systems, as well as for improving the balance between the efficacy and the toxicity of targeted therapeutic interventions. Regarding personalized medicine, it can be reasoned that only in patients which show high levels of target site accumulation, and which respond well to the first couple of treatment cycles, targeted therapy should be continued, and that in those in which this is not the case, other therapeutic options should be considered. Based on these insights, we expect that ever more efforts will be invested in developing theranostic nanomedicines, and that these systems and strategies will contribute substantially to realizing the potential of personalized medicine.

[1]  D. Kerr,et al.  Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Oyen,et al.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  K. Ulbrich,et al.  Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Hisataka Kobayashi,et al.  Nano-sized MRI contrast agents with dendrimer cores. , 2005, Advanced drug delivery reviews.

[5]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Ashish Ranjan,et al.  Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound , 2011, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[7]  Fabian Kiessling,et al.  Nanotheranostics and image-guided drug delivery: current concepts and future directions. , 2010, Molecular pharmaceutics.

[8]  I. Jacobs,et al.  Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. , 2010, Biomaterials.

[9]  Duxin Sun Nanotheranostics: integration of imaging and targeted drug delivery. , 2010, Molecular pharmaceutics.

[10]  T Lammers,et al.  Tumour-targeted nanomedicines: principles and practice , 2008, British Journal of Cancer.

[11]  J. Davies,et al.  Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.

[12]  H. Grüll,et al.  A temperature-sensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery. , 2009, Journal of the American Chemical Society.

[13]  K. Ulbrich,et al.  Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.

[14]  Jin Xie,et al.  Nanoparticle-based theranostic agents. , 2010, Advanced drug delivery reviews.

[15]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[16]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Ulbrich,et al.  Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy , 2008, British Journal of Cancer.

[18]  M. Dewhirst,et al.  Chemodosimetry of in vivo tumor liposomal drug concentration using MRI , 2006 .

[19]  E. Terreno,et al.  In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Mauro Ferrari,et al.  Seven challenges for nanomedicine. , 2008, Nature nanotechnology.

[21]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Roel Deckers,et al.  Ultrasound triggered, image guided, local drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[23]  M. Bock,et al.  Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. , 2006, Bioconjugate chemistry.

[24]  S. Wise Nanocarriers as an emerging platform for cancer therapy , 2007 .

[25]  M. Dewhirst,et al.  In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery , 2004, Magnetic resonance in medicine.

[26]  Shelton D Caruthers,et al.  Nanotechnological applications in medicine. , 2007, Current opinion in biotechnology.

[27]  Fabian Kiessling,et al.  Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy , 2010 .